[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100648609":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":12,"centralContacts":20,"locations":31,"responsibleParty":142,"collaborators":10,"id":144,"slug":145,"hasResults":146,"nctId":147,"briefTitle":148,"officialTitle":148,"acronym":149,"eligibilityCriteria":150,"healthyVolunteers":146,"sex":151,"minAge":152,"maxAge":10,"enrollmentInfo":153,"targetDuration":156,"studyType":157,"phases":10,"briefSummary":158,"conditions":159,"keywords":161,"overallStatus":34,"whyStopped":10,"lastUpdateSubmitDate":165,"lastUpdatePostDateStruct":166,"startDateStruct":169,"completionDateStruct":171,"leadSponsor":173,"locationsCount":174},{"fullName":5,"class":6},"Hellenic Cooperative Oncology Group","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":10},"mPDAC patients",null,"mPDAC patients receiving NalIriFox as a first line therapy",[13,17],{"name":14,"affiliation":15,"role":16},"Athina Christopoulou, MD, PhD","Oncology Unit, General Hospital of Patras \"Agios Andreas\"","PRINCIPAL_INVESTIGATOR",{"name":18,"affiliation":19,"role":16},"George Papaxoinis, MD","2nd Dept of Medical Oncology, \"Agios Savvas\" Anti Cancer Hospital",[21,27],{"name":22,"role":23,"phone":24,"phoneExt":25,"email":26},"Ioanna Mitrentsi, PhD","CONTACT","+30 2106912520","24","i_mitrentsi@hecog.ondsl.gr",{"name":28,"role":23,"phone":24,"phoneExt":29,"email":30},"Maria Moschoni","12","m_moschoni@hecog.ondsl.gr",[32,50,61,72,80,91,101,114,128],{"facility":33,"status":34,"city":35,"state":10,"zip":36,"country":37,"countryCode":38,"cosmosGeoPoint":39,"geoPoint":44,"contacts":45},"Attikon University General Hospital","RECRUITING","Athens","124 62","Greece","GR",{"type":40,"coordinates":41},"Point",[42,43],23.72784,37.98376,{"lat":43,"lon":42},[46],{"name":47,"role":23,"phone":48,"phoneExt":10,"email":49},"kotsantis","+30 21 0583 1000","ikotsantis@gmail.com",{"facility":51,"status":34,"city":35,"state":10,"zip":52,"country":37,"countryCode":38,"cosmosGeoPoint":53,"geoPoint":55,"contacts":56},"General Oncology Hospital Agioi Anargyroi","145 64",{"type":40,"coordinates":54},[42,43],{"lat":43,"lon":42},[57],{"name":58,"role":23,"phone":59,"phoneExt":10,"email":60},"Fotis Tzoudas","+30 21 0350 1500","fotis_tzoudas@hotmail.com",{"facility":62,"status":34,"city":35,"state":10,"zip":63,"country":37,"countryCode":38,"cosmosGeoPoint":64,"geoPoint":66,"contacts":67},"HYGEIA Hospital","151 23",{"type":40,"coordinates":65},[42,43],{"lat":43,"lon":42},[68],{"name":69,"role":23,"phone":70,"phoneExt":10,"email":71},"rigakos","+30 21 0686 7000","grigakos@oncologists.gr",{"facility":62,"status":34,"city":35,"state":10,"zip":63,"country":37,"countryCode":38,"cosmosGeoPoint":73,"geoPoint":75,"contacts":76},{"type":40,"coordinates":74},[42,43],{"lat":43,"lon":42},[77],{"name":78,"role":23,"phone":70,"phoneExt":10,"email":79},"alexios Strimpakos","astrimpakos@hygeia.gr",{"facility":81,"status":34,"city":35,"state":10,"zip":82,"country":37,"countryCode":38,"cosmosGeoPoint":83,"geoPoint":85,"contacts":86},"2nd Oncology Department, Metropolitan Hospital","185 47",{"type":40,"coordinates":84},[42,43],{"lat":43,"lon":42},[87],{"name":88,"role":23,"phone":89,"phoneExt":10,"email":90},"George Oikonomopoulos","+30 21 0480 9000","goik77@yahoo.com",{"facility":92,"status":34,"city":35,"state":10,"zip":10,"country":37,"countryCode":38,"cosmosGeoPoint":93,"geoPoint":95,"contacts":96},"Ippokratio",{"type":40,"coordinates":94},[42,43],{"lat":43,"lon":42},[97],{"name":98,"role":23,"phone":99,"phoneExt":10,"email":100},"Gkotzamanidou","+30 2132089511","mgkotzamanidou@yahoo.com",{"facility":102,"status":34,"city":103,"state":10,"zip":10,"country":37,"countryCode":38,"cosmosGeoPoint":104,"geoPoint":108,"contacts":109},"Larissa University General Hospital","Larissa",{"type":40,"coordinates":105},[106,107],22.42112,39.62847,{"lat":107,"lon":106},[110],{"name":111,"role":23,"phone":112,"phoneExt":10,"email":113},"Kotsakis","+30 2413502124","thankotsakis@hotmail.com",{"facility":115,"status":34,"city":116,"state":10,"zip":117,"country":37,"countryCode":38,"cosmosGeoPoint":118,"geoPoint":122,"contacts":123},"General Hospital Agios Andreas","Pátrai","263 32",{"type":40,"coordinates":119},[120,121],21.73508,38.2462,{"lat":121,"lon":120},[124],{"name":125,"role":23,"phone":126,"phoneExt":10,"email":127},"Athina Christopoulou","+30 261 360 1000","athinachristo@hotmail.com",{"facility":129,"status":34,"city":130,"state":10,"zip":131,"country":37,"countryCode":38,"cosmosGeoPoint":132,"geoPoint":136,"contacts":137},"Thessaloniki General Hospital \"George Papanikolaou\"","Thessaloniki","570 10",{"type":40,"coordinates":133},[134,135],22.93493,40.64072,{"lat":135,"lon":134},[138],{"name":139,"role":23,"phone":140,"phoneExt":10,"email":141},"Elena Fountzilas","+30 231 330 7000","elenafou@gmail.com",{"type":143,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100648609","hellenic-evaluation-of-the-long-term-safety-and-efficacy-of-nalirifox-as-a-1st-line-therapy-in-metastatic-pancreatic-ductal-adenocarcinoma-mpdac-100648609",false,"NCT07723261","Hellenic Evaluation of the Long-Term Safety and Efficacy of NalIriFOx as a 1st-line Therapy in Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC)","HELIOS","Inclusion Criteria:\n\n* Patients with histologically or cytologically proven metastatic PDAC\n* 1st line treatment with NalIriFOx according to physician's choice\n* Patients willing to provide a Written Informed Consent\n\nExclusion Criteria:\n\n* Patients not matching the above-mentioned inclusion criteria\n* Neoadjuvant or adjuvant treatment within 6 months from enrolment\n* Prior treatment with Liposomal irinotecan\n* Prior treatment of pancreatic cancer in the metastatic setting with chemotherapy or investigational therapy","ALL","18 Years",{"count":154,"type":155},70,"ESTIMATED","12 Months","OBSERVATIONAL","This is multicenter, prospective, open label, non-interventional study that will collect real-world data (RWD) on the clinical efficacy and safety of NalIriFOx as a first-line therapy in metastatic pancreatic ductal adenocarcinoma (mPDAC).",[160],"Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)",[162,163,164],"mPDAC","NalIriFOx","safety","2026-07-23",{"date":167,"type":168},"2026-07-24","ACTUAL",{"date":170,"type":168},"2026-03-30",{"date":172,"type":155},"2029-03-30",{"name":5,"class":6},9]